INOVIQ Exosome Diagnostic Solutions
INOVIQ CY23 achievements
Focuse
on advancing the development and commercialisation of
our SubB2M and EXO-NET platforms
For personal use only
Clinically validated SubB2M technology and commenced BC monitoring study to enable partnering
for LDT commercialisation
Developed, validated and commissioned high-throughput EXO-NET exosome isolation system to
enable a complete exosome concept-to-clinic diagnostics solution
Secured commercial partners for EXO-NET with Promega and ResearchDx to drive future revenues
Progressed pipeline of EXO-NET research tools, SubB2M tests and exosome diagnostics
Initiated discussions for potential co-development of exosome diagnostics (using EXO-NET)
Expanded Board with the appointment of experienced director, David Williams, as Chairman elect¹
Excellent clinical
⚫data for
SubB2M/CA15-3
breast cancer
test announced
INOVIQ
INOVIQ announces global joint
marketing agreement with
Promega
Promega
INOVIQ &
ResearchDX
Sign a license and
supply agreement
for the provision
of EXO-NET
enabled diagnostic
services in the USA
INOVIQ
INOVIQ
EXO-NET
5
1. Subject to shareholder approval at upcoming INOVIQ AGM on 29 Nov 23
INOVIQView entire presentation